Brainstorm cell therapeutics announces peer reviewed publication of nurown's® phase 3 study for als in muscle and nerve

New york, dec. 13, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of phase 3 clinical data in muscle and nerve. the paper, entitled "a randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis," can be found here.
BCLI Ratings Summary
BCLI Quant Ranking